Umirolimus

Drug Profile

Umirolimus

Alternative Names: A9; AXXESS; Ba9; BioFreedom; Biolimus A9 (BA9); Biolimus A9-eluting stent; Biolimus-A9; BioMatrix; BioMatrix Flex; BioMatrix NeoFlex; BMX-J; Custom NX; Nobori; TRM-986

Latest Information Update: 10 Feb 2015

Price : $50

At a glance

  • Originator Biosensors International Pte Ltd
  • Developer Biosensors International Group; Terumo
  • Class Macrolides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis
  • Phase III Coronary artery disease

Most Recent Events

  • 21 Apr 2017 Biosensors Europe plans a clinical trial for Coronary artery disease in Switzerland and United Kingdom (NCT03118895)
  • 09 Feb 2015 Biosensors International Group completes enrolment in the phase III Leaders Free Japan trial in Coronary artery disease in Japan (NCT02348021)
  • 12 Nov 2014 Biosensors International Group signs an agreement with Terumo Corporation to distribute a private label version of Nobori™ in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top